CellaVision AB Good profitability despite negative COVID-19-effect - Seite 4
CellaVision DC-1 has now entered full-scale series production after a step-by-step ramping up of production in 2019. As an effect of the ongoing pandemic, demand for CellaVision DC-1 has been limited during the second quarter of the year.
During the first quarter of the year, we submitted our application to the FDA (510k) for market clearance in the US for CellaVision DC-1 and preparations for the launch in 2021 are in full swing. The process of market approval in China for CellaVision DC-1, initiated in the first quarter of the year, is also proceeding according to plan.
The new software for the veterinary market was completed and released to the market during the quarter. The software makes it possible to run the veterinary application on CellaVision DC-1 Vet and Sysmex DI-60. A unique function for CellaVision DC-1 Vet included in the software, is the ability to also classify avian blood. This feature is expected to open up new business opportunities. In addition, the software will also contain workflow improvements for all systems.
Our long-term strategy remains
Geographic expansion and innovation are CellaVision´s core areas and we continue to increase investment to secure our future position in our market segment and maintain strong growth as soon as the effects of COVID-19 subside and the world returns to a more normalized state.
In May, I informed the Board of Directors that I wish to leave CellaVision. The recruitment process to find my successor is initiated and I will continue in my current role during the notice period and leave on November 28, 2020 at the latest. The decision to leave CellaVision was difficult on many levels. CellaVision is a fantastic company, in a very strong momentum, with a strong international marketing organization, a gradually expanded development organization and an experienced and skilled management team.
President and CEO
|EBITDA margin, %||31||37||31||37||32|
|Profit/loss before tax||34,4||37,9||59,8||72,8||129,2|
|Total cash flow||18,1||-23,8||12,9||21,2||-67,3|
|Equity ratio, %||60||74||60||74||54|
Questions concerning the interim report can be addressed to: